JAZZ Q4 2017 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$436M+10.0% YoY

Gross Profit

$411M94.2% margin

Operating Income

$141M32.4% margin

Net Income

$232M53.2% margin

EPS (Diluted)

$3.79

QoQ Revenue Growth

+6.0%

Cash Flow

Operating Cash Flow

$205M

Free Cash Flow

$188M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$5.1B

Total Liabilities

$2.4B

Stockholders' Equity

$2.7B

Cash & Equivalents

$386M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$436M	$397M	+10.0%
Gross Profit	$411M	$363M	+13.3%
Operating Income	$141M	$166M	-14.7%
Net Income	$232M	$117M	+99.0%

Revenue Segments

Xyrem

$312M73%

Erwinaze And Erwinase

$48M11%

Defitelio

$36M8%

Vyxeos

$24M6%

Prialt

$6M1%

Other Products

$3M1%

Geographic Segments

UNITED STATES

$395M90%

Europe

$39M9%

Other Countries

$3M1%